Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Nov
17
Today In Oncology
Pancreatic Cancer Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
SABR May Be Comparable to Surgery for Early-Stage NSCLC
MD Anderson Launches 2.5 Billion Philanthropic Campaign
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo